Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma ; volume:13 ; number:1 ; day:19 ; month:9 ; year:2022 ; pages:1-10 ; date:12.2022
Nature Communications ; 13, Heft 1 (19.9.2022), 1-10, 12.2022
- Creator
-
Patterson, Andrew
Auslander, Noam
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-022-32838-4
- URN
-
urn:nbn:de:101:1-2022112009055516643754
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Patterson, Andrew
- Auslander, Noam
- SpringerLink (Online service)
Other Objects (12)
Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
MEK targeting in N-RAS mutated metastatic melanoma
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
Immune checkpoint inhibitor triggered parkinsonism in a patient with metastatic melanoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
Diffuse Metastatic Melanoma in the GI Lumen Following Immune Checkpoint Inhibitor Colitis Treatment
Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
MEK targeting in N-RAS mutated metastatic melanoma
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
Immune checkpoint inhibitor triggered parkinsonism in a patient with metastatic melanoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
Diffuse Metastatic Melanoma in the GI Lumen Following Immune Checkpoint Inhibitor Colitis Treatment
Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
MEK targeting in N-RAS mutated metastatic melanoma
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma
Immune checkpoint inhibitor triggered parkinsonism in a patient with metastatic melanoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study